TP53 and colorectal carcinoma: Potential explanations could be that: (1) SOX30 could decrease chemoresistance in CRC cells by promoting p53 transcriptional activation, thereby enhancing the effect of CRC therapy, which could directly improve the prognosis of CRC (7, 20); (2) tumor SOX30 was correlated with better tumor clinical features (above-mentioned), which could indirectly lead to better prognosis in CRC.